AVBP Valuation
Arrivent Biopharma Inc
$
21.300
- Overview
- Forecast
- Valuation
AVBP Relative Valuation
AVBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVBP is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.76
P/B
Median3y
2.26
Median5y
2.26
-9.71
FCF Yield
Median3y
-8.77
Median5y
-8.77
Competitors Valuation Multiple
The average P/S ratio for AVBP's competitors is 117.99, providing a benchmark for relative valuation. Arrivent Biopharma Inc Corp (AVBP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
LSAK
Lesaka Technologies Inc
4.490
USD
-3.44%
SOHU
Sohu.com Ltd
11.510
USD
+1.77%
GRPN
Groupon Inc
17.820
USD
-2.99%
GRVY
Gravity Co Ltd
60.150
USD
+0.86%
CWCO
Consolidated Water Co Ltd
23.170
USD
+0.13%
SNDA
Sonida Senior Living Inc
24.080
USD
+3.70%
RWAY
Runway Growth Finance Corp
9.210
USD
+1.43%
AHG
Akso Health Group
1.361
USD
-2.79%
CYD
China Yuchai International Ltd
16.610
USD
+8.56%
DDD
3D Systems Corp
2.010
USD
+6.35%
FAQ
Is Arrivent Biopharma Inc (AVBP) currently overvalued or undervalued?
Arrivent Biopharma Inc (AVBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Arrivent Biopharma Inc (AVBP) is between to according to relative valuation methord.
What is Arrivent Biopharma Inc (AVBP) fair value?
How does AVBP's valuation metrics compare to the industry average?
What is the current P/B ratio for Arrivent Biopharma Inc (AVBP) as of May 03 2025?
What is the current FCF Yield for Arrivent Biopharma Inc (AVBP) as of May 03 2025?
What is the current Forward P/E ratio for Arrivent Biopharma Inc (AVBP) as of May 03 2025?